Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$1.5 million.

  • Inhibrx Biosciences' Change in Accured Expenses fell 12512.44% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year decrease of 10549.4%. This contributed to the annual value of $35.9 million for FY2024, which is 3763.57% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Change in Accured Expenses is -$1.5 million, which was down 12512.44% from -$4.3 million recorded in Q2 2025.
  • Over the past 5 years, Inhibrx Biosciences' Change in Accured Expenses peaked at $21.8 million during Q2 2024, and registered a low of -$4.3 million during Q2 2025.
  • Its 3-year average for Change in Accured Expenses is $7.1 million, with a median of $6.2 million in 2023.
  • As far as peak fluctuations go, Inhibrx Biosciences' Change in Accured Expenses crashed by 505.43% in 2024, and later tumbled by 12512.44% in 2025.
  • Quarter analysis of 3 years shows Inhibrx Biosciences' Change in Accured Expenses stood at $17.4 million in 2023, then plummeted by 65.33% to $6.0 million in 2024, then plummeted by 125.12% to -$1.5 million in 2025.
  • Its last three reported values are -$1.5 million in Q3 2025, -$4.3 million for Q2 2025, and $2.9 million during Q1 2025.